Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind trial of gantenerumab in preclinical/early Alzheimer's disease (Japan subset of GRADUATE Prevention)
jRCT2031220468Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab with Placebo (2 arms). Primary endpoint: Change from baseline to Year 4 in PACC-5 score. Started Jan 2023; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220468.